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1. Abstract 
 
Master thesis, Programme in Medicine 
High adherence to antiretroviral treatment despite frequent adverse effects 
among people living with HIV in Dodoma, Tanzania 
Emelie Thorén, January 2015 
Institution of Biomedicine, Gothenburg, Sweden 
 
Background: To reach satisfying results from the antiretroviral treatment of HIV the 
adherence needs to be > 95 %. There are also problems with toxicity and side effects of the 
antiretrovirals that affects a lot of people worldwide. Following this, it is of great importance 
to investigate how well the antiretroviral therapy (ART) is working. 
Objectives: To examine how the ART among HIV positive patients is functioning and also 
to investigate potential differences between men and women.  
Methods: The cross-sectional study was done at a Care and Treatment Clinic in Dodoma, 
Tanzania. The 200 patients (79 men and 121 women) answered a self-administered 
questionnaire and information was collected from the medical records. 
Results: The self-reported adherence level was 88% among the participants, 75% of the 
patients suffered from any adverse effect. The non-adherent patients had a tendency towards 
more adverse effects. The knowledge about HIV transmission was low regarding mother to 
child transmission (MTCT) and blood transfusion/needles as routes of transmission. Some 
differences between sexes were found; men had lower CD4 levels, lower level of knowledge 
about HIV and a tendency towards experiencing larger economic impact due to HIV. 
Conclusions: The ART was functioning well in most aspects with a relatively high level of 
adherence, despite frequent adverse effects. Additional studies with a larger patient material 
are needed to further investigate differences between men and women for the outcome of 
therapy.  
 
 
Keywords: HIV, antiretroviral therapy, adherence, adverse effect, knowledge  
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2. Introduction 
 
2.1 Background 
 
2.1.1 HIV globally 
HIV is a major global challenge causing great health issues worldwide. As much as 78 million 
people have been infected of the virus since the beginning of the epidemic, and almost 39 
million people have died of HIV (1). The worldwide prevalence of people living with HIV 
between 15-49 years is 0.8 % (1). However, there are big differences between regions and 
countries throughout the world. At the end of 2013, there were approximately 35 million 
people in the world living with HIV (2) and in the same year 1.5 million people died of AIDS- 
related illnesses worldwide (1). This is significantly less than the highest measured numbers 
in year 2005, when about 2.3 million people died (3). The reason for the falling numbers of 
deaths due to HIV/AIDS is explained by increased access to antiretroviral therapy and also 
that the numbers of persons newly infected by HIV are decreasing (3). However, the number 
of people living with HIV are rising due to growing populations, but also as a consequence of 
the antiretroviral medication that prolongs life for a lot of HIV positive people (4). 
2.1.2 HIV in Tanzania 
The Sub-Saharan Africa is the most HIV affected region in the world. Almost 70 % of the 
new HIV infections in the world, are found in this region (2). The decline of people dying 
from AIDS-related illnesses are however especially evident in this region due to the effects of 
antiretroviral treatment. In the African region, an estimated 1.1 million people died from HIV-
related causes in 2013, 24% fewer than the 1.5 million in 2009. However, the African region 
was still home to about three in four people dying from HIV-related causes in 2013 (3). 
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The first cases of AIDS in Tanzania were discovered in 1983 and the disease has since then 
spread in all regions of the country (5). In 2013 there was an estimated 1.4 million people 
living with HIV in Tanzania and the prevalence of HIV was 5.0% in adults between 15-49 
years. There was in this year 78,000 deaths due to AIDS in the country (6). The transmission 
of HIV in Tanzania is mainly caused by heterosexual intercourse and mother to child 
transmission (MTCT) (5). In November 2004 the Ministry of Health and Social Welfare 
initiated a nationwide program that focus on improving the access to care and treatment of 
HIV. The aim was to provide ARV for as many people as possible that are eligible for 
treatment, including home-based care for HIV patients (4). 
2.1.3 Care and Treatment Clinics in Tanzania 
The Care and Treatment Clinics (CTC) in Tanzania provides antiretroviral treatment, HIV 
prevention and support to HIV positive people. The clinics also have an important function in 
the education concerning the HIV infection, how it is transmitted, risk behavior and the 
treatment and progression of disease. The clinics provide regular counseling for patients who 
are on antiretroviral treatment (ART), in particular on treatment adherence. Regular 
monitoring of patients on ART, and the ART preparedness for patients who have not yet 
started ART are significant parts in the services of CTC (4).  
This study was done at the Care and Treatment Clinic in the city of Dodoma, the official 
capital of Tanzania. About 2 million people are living in the region of Dodoma, about 
300,000 in the urban areas (7). The prevalence of HIV in the region of Dodoma is 2.9 % (8). 
The CTC at Dodoma Regional Hospital provided in 2013 care for 8352 patients ≥ 15 years. 
The same year, 502 patients were newly initiated on ART at the CTC (9). The care and 
treatment services regarding HIV in Tanzania, including the cost of ARTs, are free of charge. 
The patients do not have to pay for the CTC visits or the medication, regardless of the level of 
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adherence to treatment. The HIV care and treatment is financed by The Global Fund (10) and 
the Ministry of Health and Social Welfare in Tanzania. 
2.1.4 Antiretroviral treatment globally 
ART consists in the standard treatment of at least three anti-HIV drugs suppressing the HIV 
replication. The therapy is important in order to control the virus, suppress the HIV infection 
and stop the progression of the disease. ART can reduce both mortality and morbidity and 
also improve the quality of life for HIV positive people (11). At the end of 2013, about 11.7 
million people in low- and middle-income countries were receiving ART. This is an increase 
compared to a couple of years ago (2). However, the 11.7 million people receiving ART 
represent only 36% of the people living with HIV in low-and middle-income countries (12).  
2.1.5 Antiretroviral treatment in Tanzania 
According to the guidelines for treatment in Tanzania, the ART is initiated for patients with 
CD4 count < 350 cells/mm3 (regardless of clinical symptoms) and for patients in WHO stage 
3 and 4 (regardless of CD4 count). The four groups of ARV used in Tanzania are NRTIs 
(nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase 
inhibitors), Nucleotide analogues (Nucelotide reverse transcriptase inhibitors), and Proteas 
inhibitors (PI). The recommendations consists of a combination of three drugs – 2 NRTI+1 
NNRTI, 2 NRTI+1 PI or 3 NRTIs. Eight different triple combinations of drugs are 
recommended in the guidelines from the Ministry of Health and Social Welfare as the first 
line regimen, and the treatment is supposed to be considered to each individual with respect to 
side effects and interactions with other drugs.  
The standard first line regimen in Tanzania is a combination of zidovudine (AZT), lamivudine 
(3TC) and efavirenz (EFV), and should be prescribed to all patients if there is no 
contraindication (4). A meta-analysis comparing the severity of adverse effects between 
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efavirenz (EFV) and nevirapine (NVP) concluded that EFV showed less severe adverse 
effects, with less frequency of drug discontinuation, than NVP. That supports efavirenz based 
combination treatment as the first line treatment regimens in the future (13). 
2.1.6 Adherence 
An essential component in the treatment of HIV is adherence to ART. In the National AIDS 
Control Program in Tanzania adherence is defined as follow: “Adherence to care is defined as 
a patient’s ability to follow a care and treatment plan in the long term, attend follow up 
appointments as scheduled, take medications at prescribed times and frequencies, recognize 
side effects and seek treatment, and follow instructions regarding food and other medications, 
as well as avoid risk behaviors and practices such as drinking alcohol, having unprotected sex, 
etc.”(4).  
To reach satisfying results from the treatment the adherence to treatment needs to be > 95 %, 
which means high demands on the patients understanding and willingness to treatment (4). 
The adherence is the one most important factor to reach successful treatment. Just a few 
missed doses, leading to sub-optimal adherence, can be enough for the virus to replicate again 
and the virus in the blood increase. This can lead to development of resistance against the 
drug, and the regimen then has to be exchanged. Since cross-resistance between drugs is not 
uncommon, the drugs for treatment can be substantially limited as a consequence of poor 
adherence (14). 
Different factors influencing adherence have been identified. Access to a clinic monitoring the 
treatment, daily routines concerning the medication and the patients´ understanding of the 
consequences of poor adherence are some important factors (4). An increase in social support 
for HIV positive patients has been seen to be positively associated with adherence in a study 
done in Indonesia. The family and friends are believed to play an important role in reminding 
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the patients to take their medication, help them to collect drugs and minimize the social 
isolation and stigma that can occur with a HIV diagnosis (15). Some studies have also shown 
that adherence is mainly affected through negative coping mechanisms such as use of alcohol, 
denial and self-stigma rather than positive coping mechanisms. One way to improve 
adherence could then be to reduce these negative coping mechanisms (16).  
2.1.7 Adverse effects 
Another challenge regarding the ART is the adverse effects that occur from the treatment. 
They can be divided into three categories. The first category consists of less severe and 
transient symptoms such as nausea, mild gastric symptoms, gentle headache and CNS 
disturbances. The treatment does not usually need to be stopped due to these symptoms. The 
second category contains more severe symptoms such as more severe nausea and vomiting, 
more severe gastric upset and headache and mild neuropathy. Symptomatic treatment is often 
enough, and the ART is seldom interrupted. In the third category even more severe symptoms 
can be found. More severe peripheral neuropathy, severe anemia and hypersensitive reactions 
to NVP (including liver effects and severe skin rashes) are some examples from this category. 
These adverse effects results in interruption of the ART and replacement by another regimen 
(4). It has also been noticed that some ARTs can cause metabolic complications such as 
dyslipidemia, insulin resistance and cardiovascular diseases. The effects on the kidney due to 
ART have been discussed, and particularly tenofovir (TDF) has been associated with kidney 
injury (17).  
2.2 Aim  
The aim of this study was to examine how the antiretroviral therapy (ART) among HIV 
positive patients is functioning, and to investigate potential differences between men and 
women, at a Care and Treatment Clinic (CTC) in Dodoma, Tanzania.  
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2.3 Specific Objectives 
To analyze the following factors in patients on ART: 
 The level of self-reported adherence among patients undergoing ART and factors 
associated with suboptimal adherence. 
 The proportion of patients experiencing positive effects and adverse effects from 
ART, and if the adverse effects seem to influence the adherence. 
 The accessibility and availability to the CTC as reported by patients.  
 The effects on the patients’ economy due to HIV.  
 The level of knowledge of HIV transmission and the awareness among the patients of 
the importance of high adherence.   
2.4 Medical relevance 
HIV is one of the most severe diseases in the world. Many people globally and in Tanzania 
are affected by HIV. The treatment with antiretroviral medications has revolutionized the life 
for HIV positive people. The medication has led to reduced mortality and morbidity due to 
HIV and HIV positive people experience prolonged life compared to before the antiretrovirals 
(ARV) were introduced. However there are still some challenges concerning the antiretroviral 
treatment. To reach satisfying results from the treatment the adherence needs to be > 95 %. 
This is a very high level of adherence and requires a lot of understanding and commitment 
from the patients. There are also problems with toxicity and side effects of the antiretrovirals 
that affects many patients worldwide. Following this, it is of great importance to investigate 
how well the antiretroviral therapy is working in order to achieve adherence to treatment and 
to be able to reach successful results in the treatment of HIV patients. 
It is also interesting to investigate potential differences between sexes regarding the treatment. 
The outcome of therapy and adverse effects can possibly differ between men and women and 
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it is important to not assume that the outcomes are exactly the same between sexes. Possible 
differences may for example exist since the women are screened for HIV during pregnancy, 
while the men do not have equivalent contact with the care and treatment services. Adverse 
effects may also differ since women tend to have a lower body weight compared to the men, 
but the doses of medication are the same regardless of weight. These are only a few examples 
of why it is interesting to compare men and women regarding the antiretroviral treatment. 
This study was done to be able to identify parameters of importance for the outcome of 
therapy, and thereby be able to improve the treatment of HIV-positive people in Tanzania. It 
also involved investigation of the knowledge about the disease and how it is transmitted in 
order to be able to make prophylactic efforts to reduce the number of people infected by HIV. 
Hopefully, the results and conclusions from this study will make a small contribution to the 
future work with improvements in Dodoma. 
3. Methodology 
 
3.1 Study design  
The study was done as a cross-sectional study on consecutive patients at a Care and Treatment 
Clinic of Dodoma Regional Referral Hospital in Dodoma, Tanzania. The patients answered a 
self-administered questionnaire and information was also collected from the medical records. 
The questionnaires contained 34 questions about patient characteristics and the antiretroviral 
treatment, regarding for example sociodemographic factors, adherence and accessibility to the 
clinic. From the medical records, which were completely written in English, information was 
collected such as date for initiation of ART, date for HIV diagnosis, CD4 levels and current 
ART regimen. 
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3.2 Study population 
The participants of the study consisted of 200 HIV positive patients registered at the clinic, 79 
men and 121 women. The patients were asked to participate in the study when they were at 
their regular visit at the CTC. Participants were selected with the help of the medical records 
based on the inclusion criteria, see below. The contact with the patients was taken with the 
help of a nurse working at the CTC who was speaking both Swahili and English, and the 
patients were randomly invited to participate and giving their informed verbal consent.  
Excluded were those that refused to participate in the study or did not fulfill the inclusion 
criteria. Data about the number of patients that did not want to participate in the study was not 
collected, but there were a few patients in total.  
3.3 Inclusion criteria 
HIV-diagnosed 
≥ 18 years of age 
≥ 1 year of treatment with ARV  
3.4 Pre-testing 
The questionnaires used in the study (Appendix 1) were compiled and changes were done 
after views and opinions from the supervisors in both Sweden and Tanzania. The last version 
was sent to the supervisor in Tanzania who arranged with translations of the questionnaires 
from English to Swahili. The translation was reviewed by two different doctors working at the 
CTC, independent of each other. The questionnaires were then printed in about 15 copies and 
a pilot study was done at the CTC to evaluate the comprehension of the questionnaires and to 
be able to do corrections in order to avoid potential misunderstandings and errors in the final 
study. The questionnaires were redesigned a bit, some new translations done, and 10 
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additional patients were pre-tested before continuing. After the final corrections, the last 
version could be printed and the data used in the study could be collected.  
3.5 Data analysis/Statistics 
The collected data from the questionnaires and the medical records were entered in to 
Microsoft Excel 2010 and SPSS version 22. The data was then analyzed using SPSS. The 
limit of statistically significant result was put at a p-value less than 0.05 (Fisher´s Exact Test). 
Excluded from the analysis were patients that had not answered that specific question in the 
questionnaire, or where information from the medical records was missing. The adherence 
was estimated using the questions on 14 day recall. The number of times that a patient took 
the medication in the last 14 days was divided by the number of times the patient was 
prescribed to take the medication in the same period. If the patient took less than 95% of the 
medication as prescribed it was classified as non-adherent, and ≥ 95% was classified as 
adherent. 
3.6 Ethical considerations 
The participation in the study was voluntary and the patients could at any moment choose to 
leave the study without specific reason, and the patients could also choose not to answer a 
specific question. Information, written in Swahili, about the study and the conditions was 
given to the patients. There was no difference in the care and treatment offered to the patients 
based on if they took part in the study or chose not to participate. To guarantee confidentiality 
of the patients the questionnaires were marked with a figure that in a separate document was 
related to information found in the medical records concerning the patient. After completing 
the data collection these documents were destroyed.  
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4. Results 
 
4.1 Sociodemographics 
 
                      
          Men % Women % Total % 
                      
  
   
              
Sex 
   
  79 40% 121 60% 200 100% 
Education Never been to school 2 3% 16 13% 18 9% 
p=0.003   Primary school   50 63% 84 70% 134 67% 
    Secondary school   19 24% 16 13% 35 18% 
    High school   3 4% 3 3% 6 3% 
    University/college   5 6% 1 1% 6 3% 
Occupation Unemployed   2 3% 11 9% 13 7% 
p=0.070 
 
Employed   16 21% 19 16% 35 18% 
  
 
Self-employed   22 28% 38 31% 60 30% 
  
 
Student 
 
  3 4% 2 2% 5 3% 
  
 
Peasant/farmer   26 33% 47 39% 73 37% 
  
 
Retired 
 
  9 12% 4 3% 13 7% 
Marital status Married     45 58% 19 16% 64 32% 
p<0.001   Single     5 6% 26 22% 31 16% 
    Divorced/separated   11 14% 17 14% 28 14% 
    Widowed   5 6% 40 33% 45 23% 
    Cohabiting   10 13% 7 6% 17 9% 
    Boyfriend/girlfriend 2 3% 11 9% 13 7% 
Living conditions  Own house   54 70% 71 60% 125 64% 
p=0.227 
 
Rented house/apartment 21 27% 40 34% 61 31% 
  
 
No stable place to live 2 3% 8 7% 10 5% 
                      
 
Table 1 describes the sociodemographic characteristics. In total 200 patients were included in 
the study, and the study population consisted of 60% women and 40% men. The age of the 
participants ranged between 18 to 78 years. The mean and median age was 48 and 49 years 
for the men respectively 42 and 40 years for the women. A majority of the participants had 
gone to primary school. There was a significant lower level of education among the women 
Table 1. Sociodemographic caracteristics of the 200 participants in the study. 
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(p=0.003), 13% of the women had never been to school compared to only 3 % of the men. A 
larger proportion of the men had a higher education level compared to the women, with 24% 
in secondary school and 6 % in university/college. There was also a significant difference in 
marital status between men and women (p < 0.001), 58% of the men were married compared 
to only 16% of the women.  
 
4.2 Adherence 
 
 
 
 
As seen in figure 1 the majority of the patients were classified as adherent to treatment using 
the 14 day recall method of self-reported adherence, 12 % of the patients were not adherent to 
treatment since they took less than 95% of the prescribed medication. The proportion of men 
Figure 1. Adherence based on questions regarding 14 days recall. Patients with <95% adherence are 
classified as “non-adherent” and patients with > 95% adherence are classified as “adherent”. 
 
   
 
17 
 
that was non-adherent to treatment was a bit higher than the proportion of women, but the 
difference was not significant.  
The patients were also asked how many times in the last two weeks they had not taken the 
medicine, see figure 2. Most of the patients, 78 %, answered zero times which means that they 
had taken their medication as prescribed every day, 12 % reported that they had missed one 
time and 6 % had missed two times in the last two weeks. No significant difference was seen 
between men and women.  
 
 
 
Questions about the reasons for taking the HIV drugs (reasons for adherence) respectively not 
taking the drugs (reasons for not adherent) were also analyzed. Table 2 shows the reason for 
adherence to treatment. As seen in the figure a great majority of the patients said that the main 
reason was to live longer. No significant difference was found between men and women (p = 
0.08). 
 
Figure 2. Number of times not taking the HIV drugs the last 14 days.  
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Table 2. The reason for taking the HIV drugs (reason for adherence) 
 
 
Total Men Women 
What is the main reason 
for taking your HIV 
drugs? 
To get cured from HIV  8 3 11 
 10% 3% 6% 
To avoid getting symptoms 
of HIV 
 6 7 13 
 8% 6% 7% 
The doctor tells me to take 
the medicine 
 1 1 2 
 1% 1% 1% 
To live longer  63 109 172 
 81% 91% 87% 
Total  78 120 198 
 100% 100% 100% 
 
 
 
 
Men Women Total P-value 
        n=43 n=46 n=89   
Simply forgot     56% 74% 65% 0.08 
Not enough pills at home 
 
16% 4% 10% 0.08 
No time to get new pills   9% 2% 6% 0.19 
Not enough money to get new pills 2% 4% 3% 1.00 
No access to a clinic to get new pills 5% 0% 2% 0.23 
Because of the side effects 
 
7% 12% 10% 0.25 
Other reason     21% 31% 26% 0.34 
 
 
Table 3 shows the answer on the question “If you didn’t take your medication at any point, 
what was the reason?”. Most of the patients, 65%, said that the reason was that they simply 
forgot to take the pills. “Travelling” and “went to funeral” were the most common answers in 
the category “others”. Men tended to report more often that they did not have enough pills at 
home, and more women answering that they simply forgot.  
 
 
Table 3. The reason for not taking the HIV drugs (reason for not adherent) 
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4.3 ART and adverse effects 
 
Table 4. The current treatment with ART among the patients at the CTC.  
 
Sex 
Total Men Women 
Current treatment with 
ART 
AZT+3TC+NVP  12 30 42 
 15% 25% 21% 
AZT+3TC+EFV  27 34 61 
 34% 28% 31% 
TDF+FTC+EFV  26 37 63 
 33% 31% 32% 
TDF+FTC+NVP  0 1 1 
 0% 1% 1% 
TDF+FTC+LPV/r  6 10 16 
 8% 8% 8% 
TDF+FTC+ATV/r  4 4 8 
 5% 3% 4% 
TDF+3TC+EFV  1 3 4 
 1% 3% 2% 
AZT+3TC+LPV/r  1 1 2 
 1% 1% 1% 
AZT+3TC+ATV/r  1 0 1 
 1% 0% 1% 
ABC+3TC+ATV/r  1 0 1 
 1% 0% 1% 
ABC+3TC+LPV/r  0 1 1 
 0% 1% 1% 
Total  79 121 200 
 100% 100% 100% 
 
The current antiretroviral combination regimens used among the participants in the study 
could be seen in table 4. Regarding the type of ARV used, there was no significant difference 
between men and women (p = 0.66). Nor was there any significant connection between type 
of ART and adherence (p = 0.21).  
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Regarding the number of times per day taking the ARTs, 38% of the patients were taking the 
medication 1 times a day, 60% two times a day, and 2% of the patients 3 times a day. There 
was no significant association between times per day taking the ART and adherence (p=0.43). 
The proportions of patients with positive effects could be seen in table 5. A majority of the 
patients reported that their health status after started with ART was “much better” or “better”. 
A very small portion of patients felt “the same” or “worse”. More women said that their 
health is “much better”, and a larger proportion of the men answered “better” compared to the 
women (p=0.03). 
Table 5. The proportion of patients with positive effects of ART.  
 
 
Total Men Women 
Compared to before you 
started treatment, how 
would you describe your 
health status now? 
Much worse  1 0 1 
 1% 0% 1% 
The same  0 1 1 
 0% 1% 1% 
Better  33 32 65 
 42% 26% 33% 
Much better  45 88 133 
 57% 73% 67% 
Total  79 121 200 
 100% 100% 100% 
 
The adverse effects of the treatment could be seen in table 6. Only 25% of the patients did not 
experience any adverse effect. About one fifth of the patients experienced nausea, rashes/skin 
lesions, reduced sensibility/numbness and muscle pain/joint pain. More men were suffering 
from diarrhea (p = 0.01). Otherwise, no significant difference between sexes could be seen. 
There were a lot of different answers in the alternative “others”, e.g. loss of appetite, anxiety, 
back pain and fatigue.  
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The connection between type of ART and the incidence of any side effect was investigated, 
but no significant correlation could be seen (p = 0.93). When comparing EFV-based regimens 
with NVP-based regimens, more of the patients with EFV-based regimens were suffering 
from nightmares, 17 % compared to 5 % of the patients on NVP-based treatment (p=0.04). 
There were no significant differences found regarding the incidence of dizziness, problems to 
sleep or rashes/skin lesions.  
Adverse effects  Men Women Total P-value 
      n=78 n=121 n= 199   
Nausea     22% 18% 20% 0.59 
Vomiting     5% 2% 3% 0.21 
Diarrhea     15% 3% 8% 0.01 
Abdominal pain   17% 12% 14% 0.40 
Rashes/Skin lesions   18% 20% 19% 0.85 
Nightmares   17% 13% 15% 0.54 
Problems to sleep   6% 10% 9% 0.45 
Dizziness     15% 15% 15% 1.00 
Reduced 
sensibility/numbness 22% 21% 21% 0.86 
Fat loss in arms, legs or face 3% 6% 5% 0.49 
Severe weight loss   9% 12% 11% 0.50 
Muscle pain/joint pain 19% 17% 18% 0.70 
Other     5% 9% 8% 0.41 
No adverse effects   23% 26% 25% 0.62 
Table 7. Adverse effects in relation to adherence.  
 
Adherence 
Total 
<95% = non-
adherent 
>95% = 
adherent 
 Any  
adverse effect 
 20 121 141 
 91% 72% 74% 
No  
adverse effect 
 2 48 50 
 9% 28% 26% 
Total  22 169 191 
 100% 100% 100% 
Table 6. Adverse effects experienced by the patients in the last 6 months of treatment.  
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As seen in table 7, the non-adherent patients had a tendency towards more adverse effects, 
91% compared to 72 % among the adherent patients (p = 0.07). 
 
4.4 ART and CD4 level 
 
Table 8 shows the latest measured CD4 levels, 15 % of the patients had current CD4 levels 
below 200 cells/mm3. More men had lower CD4 levels (p=0.005). 
 
Table 8. Latest CD4 levels.  
 
 
Total Men Women 
Latest CD4 level 0-199  14 15 29 
 18% 12% 15% 
200-399  37 37 74 
 47% 31% 37% 
400-599  21 37 58 
 27% 31% 29% 
≥ 600  7 32 39 
 9% 26% 20% 
Total  79 121 200 
 100% 100% 100% 
 
 
 
The difference in CD4 cell counts between the latest value and the level when started ART 
can be seen in figure 3. All but eight of the men and eight of the women have risen in CD4 
since started treatment. Most of the patients have risen with about 200-250 cells/mm3. Mean 
= 264, median = 209, range -239 to 1027.  
The mean time of duration of ART was in this study 58 months.  
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Figure 3. The difference in CD4 since the start of ART.  
 
 
The difference in CD4 between the latest and the highest measured value could be seen in 
table 9. Among 40% of the patients the latest CD4 value was also the highest (the difference = 
0). The other 60% of the patients had decreased in CD4 since the highest measured. Only the 
ones who had decreased in CD4 more than 200 cells/mm3 have been analyzed here. In total, 
21 % of the patients had decreased in CD4 more than 200 cell/mm3. There was no significant 
difference between men and women (p = 0.48). 
 
CD4 difference Frequency Percent % 
 <-200 41 21 
>-200 159 80 
Total 200 100 
  
Table 9. Difference in CD4 since the highest measured value.  
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4.5 Knowledge about HIV 
 
 
Correct answers   Men Women  p-value Total 
    n= 78 n = 121  n= 199 
Shaking hands (no)   100% 100% - 100% 
Kissing (no)   91% 98% 0.05 95% 
Sharing the same food/drink (no) 100% 100% - 100% 
From mother to child during   51% 66% 0.04 60% 
pregnancy/breastfeeding (yes)      
Having sex with condom (no)  97% 98% 0.65 98% 
Having sex without condom (yes) 95% 93% 0.57 94% 
Through blood, e.g. needles,   76% 73% 0.74 74% 
transfusion of blood (yes)      
Insects/mosquito bites (no)  99% 98% 1.00 99% 
 
The knowledge about the routes for transmission could be seen in table 10. The knowledge 
was not good regarding “mother to child-transmission” and “through blood”. Fewer of the 
men new about mother to child transmission, and more of the men thought that kissing was a 
route of transmission.  
On the question “Are there any ways to cure HIV/AIDS?”  58 % of the patients chose the 
correct answer (“no”), 34 % did not know and 9 % thought that HIV was curable. There was 
no significant difference between men and women.  
The information to the patients about the importance of adherence was good, 85% had got the 
information multiple times with detailed information. No significant difference between 
sexes. The awareness of high adherence among the patients showed that men had a lower 
knowledge than women about the fact that the ART could stop working if the adherence was 
poor (59% out of 78 men compared to 74% out of 121 women, p = 0.03). However, about 
80% of both the men and the women knew that the symptoms of HIV could come back or 
increase due to poor adherence.  
Table 10. Believed routes of HIV transmission. The percentage shows the proportion of 
correct answers, 
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4.6 Economy, availability and accessibility 
 
Regarding the availability and access to the clinic, 94 % of the patients answered that the 
availability/access was good. Only 6 % thought that it was difficult to contact the clinic and 
get a visit to the CTC. No significant difference was found between men and women.  
 
 
Table 11 shows that most of the patients, 41% came to the CTC by bus. More men were 
travelling by bicycle and motorcycle and a greater proportion of women came by bus. In total, 
15% of the patients had travelled more than three hours to get to the clinic. As much as 80 % 
of the patients experienced the costs of travelling as moderate, low or not mentionable. 
However, about 20% answered that the costs were high or not even bearable. A majority of 
the patients, 94%, had never let down their medication due to economic consequences. No 
significant difference was seen between sexes.  
              Men % Women % Total  % 
How do you travel to get to the 
clinic? 
 
Walking   16 20% 28 23% 44 22% 
(p=0.001)        By car   21 27% 36 30% 57 29% 
          By bus   27 34% 54 45% 81 41% 
          By bicycle 9 11% 0 0% 9 5% 
          By motorcycle 6 8% 3 3% 9 5% 
How long time do you travel  
to the clinic? <30 min 25 32% 21 17% 46 23% 
(p=0.136) 
    
30 min - 1 hour 29 37% 45 37% 74 37% 
  
    
1 hour - 2 hours 15 19% 36 30% 51 26% 
  
    
3 hours - 4 hours 7 9% 11 9% 18 9% 
  
    
>4 hours 3 4% 8 7% 11 6% 
How big are the economic costs of 
travel  
Not 
mentionable    5 6% 6 5% 11 6% 
to the clinic for you?     Low    20 26% 27 22% 47 24% 
(p=0.128)         Moderate 41 53% 59 49% 100 50% 
          High   12 15% 20 17% 32 16% 
          Not bearable 0 0% 9 7% 9 5% 
Table 11. Ways of travelling to the CTC and economic costs for travelling. 
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As seen in table 12, a tendency could be seen towards more men with negative impact on their 
economy compared to the women (p = 0.073), 46% of the men said that living with HIV had 
made their economy worse.  
 
Table 12. Economic impact due to HIV. 
 
 
Total Men Women 
Do you think that living 
with HIV has made your 
economy worse than if 
you were all healthy? 
   Yes  36 39 75 
 46% 32 % 38% 
   No  43 82 125 
 54% 68% 63% 
Total  79 121 200 
 100% 100% 100% 
 
Among the patients that answered that HIV had made their economy worse, the reason for 
this was reported by the patients, see figure 4. No significant difference was found between 
men and women.  
 
Figure 4. The reason for worsening of the economy due to HIV (n=66). The most common answer in 
“other reason” was that HIV had made the health worse, which negatively affected the ability to work.  
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5. Discussion  
 
5.1 Sociodemographic factors 
The participants in this study had mainly gone to primary school (67%). However 9 % of the 
patients had never been to school. Regarding to statistics from Unicef, the enrolment ratio in 
primary school is 98.2% in Tanzania (18). Since the mean age in this study was 48 (men) and 
42 (women) years, it is possible that the enrolment ration in primary school was lower a 
couple of decades ago. The attendance ratio in secondary school is now between 24-26 % 
(18). In this study only 18% had gone to secondary school. The education level was in general 
higher for the men compared to the women.  
Regarding the marital status, more of the women were single or widowed compared to the 
men. It could be speculated that this is because their former partners have already passed 
away in HIV/AIDS. Since women tend to be married to slightly older men, and the most 
common route of transmission for adults in Tanzania is through heterosexual intercourse, this 
could be an explanation. The larger proportion of women being single compared to the men 
can be speculated about as well. Possibly, it is more difficult for HIV positive women to find 
a new partner when living with HIV. A recent study about the association between HIV status 
and marriage dissolution suggested that there were difference between sexes. Higher HIV 
prevalence was more common among formerly married women compared to formerly married 
men (19).  
5.2 Adherence  
The level of self-reported adherence in this study was 88 %. Adherence was in this case 
defined as patients taking more than 95 % of the medication, and these patients were 
classified as adherent to treatment. A meta-analysis regarding the adherence levels in Sub-
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Saharan Africa (SSA) compared to North America showed 77 % adherence levels in SSA 
(20), which indicates lower levels of adherence compared to this study. However, there is a 
broad variation of adherence level between different studies, and the adherence in this study is 
consistent with other studies done in Tanzania (21-23) with similar levels. It is important to 
consider the possibility that many of the patients with high adherence are the ones that are still 
attending the CTC, while the ones with low levels of adherence might have a lower 
attendance to the clinic. Patients with very low adherence to treatment are more likely to drop 
out from the care and treatments offered by the CTC, and also have a higher risk of mortality 
in the long term. Since these patients are not included in the study there is some risk that the 
level of adherence is overestimated.  
The results also showed that 78% of the patients had taken their medication every day, and a 
falling percentage scale had missed 1, 2, 3 times and so on in the last 14 days. The relatively 
high levels of adherence and low levels of missed doses found in this study are of course 
beneficial for the outcome of therapy. The adherence is crucial for the success of ART and 
suboptimal adherence leads to resistance to ARV, immunological decline and quicker 
progression of the disease (21). The most frequent reason for being adherent was to live 
longer, 6 % answered to get cured from HIV. Since HIV is not curable, this could indicate a 
poor knowledge among the patients considering this. The reason for not taking the HIV drugs 
(not being adherent to treatment) was mainly forgetfulness. The second most common answer 
was “other reason”, for instance travelling and going to funeral. Travelling, transport costs 
and forgetfulness have also been mentioned as common reasons for not taking the medication 
in other studies (24). Regarding the factors for suboptimal adherence that were investigated, 
no statistical association was found with sex, type of ART combination regimen, number of 
times per day taking the ART or the presence of adverse effects from the treatment. There was 
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however a tendency towards association between the presence of adverse effects and low 
adherence. This connection has been found in several previous studies as well (24, 25). 
5.3 Positive effects and adverse effects 
The positive effects on health since starting the antiretroviral treatment were in a great 
majority of the patients prominent. All but two of the patients answered that their health status 
had become better or much better.  This means that the ART can be considered as successful 
for most of the patients with good treatment outcome. Women tended to choose “much better” 
more often than men, but the underlying reason for this is hard to know. Despite improvement 
of health status when being on ART, a great proportion of the patients were also suffering 
from adverse effects, 75% of the patients experienced any adverse effect. The most frequent 
symptoms were nausea, rashes/skin lesions, sensibility disturbances and muscle/joint pains. 
When putting together “nightmares” and “problems to sleep” the total proportion of patients 
becomes 24% experiencing effects on the sleep. Men experienced diarrhea for a greater extent 
than the women. The reason for this is not known, and there was no significant difference 
between sex and current ART that could explain the difference. More of the patients on EFV-
based regimens had nightmares compared to the ones on NVP-based regimens. This could 
probably be explained by the CNS adverse effects caused by efavirenz (EFV) (4, 13). The 
known adverse effect of rashes/skin symptoms caused by nevirapine (NVP) (4, 13) did 
however not show any significant association in this study. 
5.4 CD4 levels and antiretroviral treatment 
Most of the patients in this study had a current CD4 value above 200 cells/mm3 and can be 
considered to have an effective treatment. However, 15% had a CD4 below 200 cells/mm3, 
which indicates that the treatment is not very successful. This can have several different 
reasons such as poor adherence to treatment resulting in decreased immunological response or 
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the development of drug resistance to the current treatment. Another possible reason is that 
the ART was initiated at a very late stage of HIV infection, with limited possibility to increase 
the CD4 levels. The baseline immunologic and clinical status has been found to be a 
significant predictor of HIV-related morbidity and mortality (26, 27). 
The men tended to have lower CD4 levels in general, 18% had less than 200 cells/mm3 and a 
smaller proportion of the men had really high levels above 600 cells/mm3. The reason to this 
cannot be explained by lower adherence, difference in current ART or higher amount of 
adverse effects, since none of this had shown any significant differences compared to women 
in this study. A previous study from Tanzania has also shown that men were more 
immunosuppressed with CD4 levels lower than the women. Suboptimal adherence and 
advanced immunodeficiency at enrollment were some findings associated with this, but could 
not explain the whole difference (28). Since the women regarding to the guidelines in 
Tanzania is offered an HIV test when pregnant, the HIV infection can often be detected in an 
earlier stage (4). The men tend to have more advanced stage of HIV at disease presentation, 
which makes them less likely to respond well to ART, according to previous studies (29). 
Besides the latest CD4 levels, the difference in CD4 was measured since started ART. This 
shows that a great majority of the patients had increased in CD4 since started ART, which can 
be considered as successful antiretroviral treatment (4). The results also showed that about 20 
% of the patients had decreased in CD4 more than 200 cells/mm3 since the highest measured 
CD4 level. This could possibly show an ongoing treatment failure, indicating suboptimal 
adherence to treatment. However, the decrease in CD4 might also be a consequence of 
opportunistic infections or concomitant diseases resulting in low CD4 levels.  
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5.5 Knowledge 
The knowledge about transmission routes for HIV through blood transfusion/needles was only 
74%. Mother to child transmission (MTCT) was also less known, particular among the men. 
Only about half of the men knew about MTCT as a possible transmission route of HIV. 
Furthermore, 9% of the men thought that kissing transmitted HIV. These results cannot be 
completely satisfying, since most of the patients have been in the care and treatment services 
for a long period of time and should have got information about routes of transmission. 
Comprehensive knowledge of HIV in Tanzania is known to be somewhat lower for the men 
compared to women in statistics from Unicef (18). It can be speculated that the knowledge 
about MTCT is lower for the men since they are not that much involved in the care and 
treatment during pregnancy and breast feeding.  
The men also had lower level of knowledge about the importance of high adherence, 
specifically that the ART could stop working due to suboptimal adherence. Since there was no 
significant difference between sexes regarding the information given about importance of 
adherence, this could not be a reason for differences between sexes. Difference in adherence 
could neither explain the differences of knowledge.  
5.6 Economy, availability and accessibility 
The accessibility and availability to the CTC experienced by the patients were good, even 
though 15% had travelled more than 3 hours. The costs of travelling were mainly considered 
as moderate-low, and could not be considered as a major obstacle for adherence or limited 
visits to the CTC. Possible economic consequences such as travel costs to get to the CTC and 
not be able to go to work did not affect the ability to take the medication, and economic 
limitations does not tend to result in suboptimal adherence. However, 38% of the patients said 
their economy were worse due to HIV. There was a tendency towards more men experiencing 
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negative effects on their economy. The main reason for this was being sick/weak which 
negatively affected the ability to work. One can assume that most of the men have the role as 
the major economic family supporter, and by this for a greater extent experienced the 
economic effects as a severe problem. 
5.7 Strength and limitations 
The strengths with this study could be described as follow. The use of questionnaires for 
answering the questions is a good way to be able to get as much confidentiality as possible. It 
is reasonable to believe that the patients answer more honestly when writing by themselves, 
instead of for example oral interview technique, especially when the questions were about 
HIV which is known to be associated with a lot of stigma. There was also a careful process 
when selecting the questions in the questionnaires. The translation was done by an English 
speaking doctor in Tanzania, and was re-checked by another Tanzanian doctor after the first 
translation, with some small corrections. Also the pre-testing phase was an important part in 
the methodology, which led to some small corrections, to make the questionnaires and the 
data collection as understandable and reliable as possible. The nurse that was involved in the 
distribution of questionnaires and oral instructions to the patients in Swahili, also contributed 
a lot to the feasibility of the study. Since the communication with the staff in English was 
easy no larger language barriers existed. Having the same person introducing the 
questionnaires and answering questions in Swahili could also be considered as a good way of 
avoid differences in the practical implementation of the study.  
However, there are also multiple limitations regarding this study. First of all, the patient 
material is quite small and the study was only done at one clinic at one of the hospitals in 
Tanzania. This means that the generalizability of the results and conclusions are limited, and 
very likely the possibility to get significant results when analyzing the data could increase 
with a larger patient material. This was unfortunately not feasible in this study, since the time 
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for data collection was quite limited. Another limitation is that for practical reasons the study 
was done as an on-treatment analysis that only included patients still visiting the CTC. 
Following this, the adherence could not be estimated on all patients who were initiated on 
ART from the beginning. Some of the patients have probably dropped out from the care and 
treatment, moved to another city or even passed away. It is also possible that the patients with 
very low adherence are not coming to the CTC, and these patients are by this not included in 
the study. The use of 14 day recall as a way of estimating the self-reported adherence can also 
be discussed. There is of course a possible risk that the patients have been more aware of 
taking the medication when the visit at the hospital is close in time. However, 14 days recall 
concerning the adherence is a reasonable period of time measuring the self-reported 
adherence, since the risk of recall bias increases when using a period further back in time.   
The use of methodology with distribution of printed questionnaires could also be discussed. 
While the possibility for confidentiality increases with patients filling out the questionnaires 
by themselves, it leads however to a selection of patients that knew how to read. Since the 
adult literacy rate in Tanzania is only 67.8 % (18), some patients are through this lost in the 
selection process. Sometimes when the participants could not read, a nurse helped them by 
reading the questions. Still, this was a limited amount of patients since the facilities and time 
was not enough to do this for a large amount of patients. Even the patients that knew how to 
read had sometimes still difficulties filling out the questionnaires, since they were not used to 
this kind of questions and ways of answering. This problem was limited by most of the time 
having a Swahili-speaking person available to assist the patients.  
Even if the confidentiality rate increased by using questionnaires instead of interviews, the 
way of being anonymous was not really possible. The patients were sitting in the same room 
close to each other when answering the questions and the other participants could hear if one 
had any questions regarding the content. Unfortunately, this could not be avoided since the 
   
 
34 
 
small amount of space at the clinic and a large flow of patients visiting the CTC. The 
collection of data from the medical records also had some difficulties. Sometimes the patients 
were transferred from another CTC, which meant that information from earlier visits could 
not be found. The information from the medical records was not always complete with for 
example date for initiation of ART and initial CD4 value missing.  
6. Conclusions  
 
 The level of self-reported adherence was high among the participants in this study. No 
statistical association was found between suboptimal adherence and sex, type of ART 
or presence of adverse events.  
 The majority of the patients experienced increased health status. However, 15 % had a 
CD4 level that was below 200 cells/mm3 and one fifth of the patients had decreased 
with more than 200 cells/mm3 compared to the highest measured level.  
 Three out of four patients reported adverse events from ART. There was a tendency 
towards more adverse effects among the non-adherent patients.  
 The patients reported good availability and accessibility to the CTC. Economic 
consequences were not a reason for suboptimal adherence. About 40% of the patients 
reported that HIV had a negative impact on their economy. The tendency was that 
more men than women experienced this negative effect.  
 Men had a lower level of knowledge about HIV compared to the women.   
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8. Populärvetenskaplig sammanfattning 
 
Hög följsamhet till antiretroviral behandling, trots många oönskade effekter bland 
människor som lever med HIV i Dodoma, Tanzania.  
HIV är en virusinfektion som orsakar nedsättning av immunförsvaret hos den som smittats. 
Utan en fungerande behandling leder sjukdomen så småningom till allvarlig immunbrist och 
utveckling till sjukdomen AIDS. HIV orsakar stort lidande över hela världen. Ett av de värst 
drabbade områdena är länderna söder om Sahara, där förekomsten av och dödligheten i HIV 
är hög. I Tanzania lever 1,4 miljoner människor med HIV, och år 2013 var det totalt 78 000 
dödsfall i sjukdomen till följd av AIDS.  
Det finns så kallad ”antiretroviral” behandling som sänker virusnivåerna i kroppen, minskar 
risken att utveckla allvarliga symptom av sjukdomen och förlänger livet för många HIV 
positiva patienter. Följsamheten till behandling är emellertid av största vikt för att läkemedlen 
ska ha bra effekt. Det kräver att patienterna tar minst 95 % av medicinerna, d.v.s. inte missar 
mer än 5% av de ordinerade doserna.  
Denna studie syftade till att undersöka hur behandlingen med antiretrovirala läkemedel 
fungerar på en HIV-klinik i Tanzania, med extra fokus på följsamheten till behandling.  
Studiens metod innebar att patienterna på kliniken fick besvara en enkät med frågor som 
berörde olika aspekter av den antiretrovirala behandlingen, däribland följsamhet till 
behandling. Totalt ingick 200 patienter i studien. Uppgifter om olika lab-värden, 
behandlingstid med mera inhämtades också från journaler.  
Resultaten visade att den antiretrovirala behandlingen som helhet fungerade väl utifrån de 
förutsättningar som gavs. Hela 88 % av patienterna var följsamma till behandlingen, vilket är 
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en relativt hög andel. Detta trots att så många som 75 % av patienterna upplevde oönskade 
symptom som sannolikt kan kopplas till behandlingen. Att ta reda på orsakerna till varför 
vissa patienter inte är följsamma till behandling är viktigt för att på sikt kunna förbättra 
effekterna av behandlingen. Ett resultat av denna studie visade att den vanligaste orsaken till 
att man inte tog läkemedlen helt enkelt var glömska. Det fanns även en viss tendens till att de 
patienter som inte var följsamma till behandlingen upplevde negativa symptom i större 
utsträckning. Studien kunde även påvisa en del skillnader mellan män och kvinnor, där 
männen generellt hade sämre kunskap om HIV och hade lägre nivåer av immunceller kallade 
CD4-celler. Det fanns även en tendens till att männen i större utsträckning upplevde en 
negativ påverkan på sin ekonomi som en följd av HIV-diagnosen.  
Framöver kan det vara intressant att ytterligare undersöka eventuella skillnader mellan 
män och kvinnor i en studie med större patientmaterial och en längre observationstid. Detta 
för att i framtiden kunna göra ännu fler förbättringar avseende den antiretrovirala 
behandlingen och riktade åtgärder för enskilda individer som står på behandling mot HIV.   
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Appendix 1 - Questionnaire 
 
Antiretroviral treatment of HIV in Dodoma, Tanzania 
This is a questionnaire concerning the HIV treatment that you undergo. This is a part of my 
master thesis as a medical student in Sweden, and will examine how the HIV treatment in 
Tanzania is functioning. The participation in the study is voluntary and confidential. You can 
choose to leave the study without specific reason. There will be no difference in the care and 
treatment offered to you based on if you take part in the study or not. I hope that you want to 
participate in the study! 
 
Instructions: Please tick the boxes for the appropriate answer. For some questions, more than 
one alternative can be chosen. Where a longer answer is required, please fill in your answers 
in the space provided. 
 
A. General questions 
 
1. Age: _______ years 
2. Sex: 
o Male 
o Female 
3. Level of education:  
o Never been to school 
o Primary school 
o Secondary school 
o High school 
o University/College 
4. Occupation: 
o Unemployed 
o Employed 
o Self-employed/business 
o Student 
o Peasant/ farmer 
o Retired 
5. Marital status: 
o Married 
o Single 
o Divorced/Separated 
o Widowed 
o Cohabiting 
o Boyfriend/girlfriend 
 
6. Living conditions: 
o Own house 
o Rented house/apartment 
o No stable place to live 
B. Treatment 
7. What is the main reason for 
taking your HIV drugs? 
o To get cured from HIV 
o To avoid getting symptoms 
of HIV 
o The doctor tells me to take 
the medicine 
o To live longer 
8. Compared to before you 
started the treatment, how 
would you describe your 
health status now? 
o Much worse 
o Worse 
o The same 
o Better 
o Much better 
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9. How many pills for HIV 
treatment are you prescribed 
per day? 
_______pills 
10. How many of the prescribed 
pills for HIV treatment did 
you take yesterday? 
_______pills 
 
11. Have you experienced any of 
the following symptoms the 
last 6 months? (you may 
choose several options)                 
o Nausea 
o Vomiting 
o Diarrhea  
o Abdominal pain 
o Rashes/skin lesions 
o Nightmares 
o Problems to sleep 
o Dizziness 
o Reduced sensibility/ 
numbness in arms or legs 
o Fat loss in arms, legs or face 
o Severe weight loss 
o Muscle pain/joint pain 
o Other__________________ 
o No bad symptoms 
12. If yes, do you believe that the 
symptoms are due to side 
effects of your medical 
treatment? 
o Yes 
o No 
o I don’t know 
13. Have you at any time not 
taken your medicine due to 
side effects from the 
medication? 
o Yes, many times 
o Maybe some time 
o No, never 
 
14. How many times per day do 
you take your HIV drugs? 
o 1 times a day 
o 2 times a day 
o 3 times a day 
15. In the past 14 days how many 
times did you not take your 
medication as prescribed? 
_______times 
16. If you didn´t take your 
medication at any point, what 
was the reason? (You may 
choose several reasons) 
o Simply forgot 
o Did not have enough pills at 
home 
o Did not have time to get 
new pills 
o Did not have enough money 
to get new pills 
o Did not have access to a 
clinic where I could get the 
pills 
o Because of the side effects 
(please 
specify)________________ 
o Other 
reason_________________ 
 
C. Accessibility, availability, 
economy 
 
17. How do you travel to get to 
the clinic? 
o Walking 
o By car 
o By bus 
o By bicycle 
o By motorcycle 
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18. How long time did you travel 
to get to the clinic? 
o Less than 30 minutes 
o 30 minutes – 1 hour 
o 1 hour – 2 hours 
o 3 hours - 4 hours 
o More than 4 hours 
19. How big are the economic 
costs of travel to the clinic for 
you? 
o Not mentionable 
o Low 
o Moderate 
o High 
o Not bearable 
20. How is the availability/access 
to the HIV-clinic?     
o It is easy to contact the 
clinic and get a visit there 
when I need to 
o It is hard to get a visit and 
to contact the clinic 
21. Do you have to pay for your 
HIV medicine? 
o Yes 
o No 
22. Have you ever let down your 
medicine due to economic 
consequences? (For example 
costs to get to the clinic, costs 
to get the pills, have to stay 
home from work etc.) 
o Yes, often 
o A few times 
o No never 
23. A. Do you think that living 
with HIV has made your 
economy worse than if you 
were all healthy? 
o Yes  
o No 
23 B. If yes, what do you think is 
the reason? 
o Expensive costs for 
medication 
o Expensive costs for visit the 
clinic including doctor visits 
o Having to stop working due 
to HIV 
o Having to change work due 
to HIV 
o Other__________________ 
 
D. Knowledge of HIV and HIV 
drugs 
 
24 How do you think HIV is 
spread from one person to 
another? (you may choose 
several options)  
o Shaking hands 
o Kissing 
o Sharing the same food/drink  
o From mother to child during 
pregnancy/breastfeeding 
o Having sex with use of 
condom 
o Having sex without condom 
o Through blood, e.g. needles, 
transfusion of blood 
o Insects/mosquito bites 
25 Are there any ways to reduce 
the risk to get infected by 
HIV?(you may choose several 
options) 
o Use condoms – safe sex 
o Abstain from sex 
o Medicine to mother during 
pregnancy and 
breastfeeding 
o Male circumcision 
26 Are there any ways to cure 
HIV/AIDS? 
o Yes 
o No 
o I don´t know 
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27 If you don´t take the HIV 
drugs continuously, may any 
of the following negative 
consequences occur from 
this?(you may choose several 
options) 
o The symptoms of HIV may 
return/increase 
o The HIV drugs can stop 
working 
o You can transmit HIV to 
others more easily 
 
28 Have you got information 
about the importance of 
taking the HIV drugs 
regularly and why it is 
important? 
o Yes, multiple times with 
detailed information 
o Yes, a few times 
o Yes, but only one time 
when I started treatment 
o No, I never got the 
information 
o I don´t know 
 
E. Contact with partners  
 
29 Do you know your partners 
HIV status? 
o Yes, positive 
o Yes, negative 
o No, I don’t know 
o I have no current sexual 
partner. (only answer 
question 33) 
 
 
 
30 Do you have sexual 
relationships with more than 
one partner? 
o Yes 
o No 
31 If yes, how many sexual 
partners do you have? (please 
specify with a number) 
______________ 
32 Do you use condom during 
sex? 
o Yes, always 
o Most of the times 
o Not very often 
o No, never 
33 The last time you had sex, did 
you use a condom? 
o Yes 
o No 
o I do not remember 
34 With which sexual partners 
have you been using 
condoms? 
o Regular partner 
o Temporary partner 
o All sexual partners 
o I do not use condoms
Thank you very much for your participation! 
Emelie Thorén, Medical Student, Sahlgrenska, Sweden 
Boniface Nguhuni, M.D, Dodoma Regional Referral 
Hospital, Tanzania 
Rune Andersson, M.D, Professor in Global Health, 
Sahlgrenska, Sweden 
 
 
   
 
 
 
 
